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StriatumMitochondrial dysfunctions have been implicated in the cellular processes underlying several neurodegen-
erative disorders affecting the basal ganglia. These include Huntington's chorea and Parkinson's disease, two
highly debilitating motor disorders for which recent research has also involved gene mutation linked to
mitochondrial deﬁcits. Experimental models of basal ganglia diseases have been developed by using toxins
able to disrupt mitochondrial function: these molecules act by selectively inhibiting mitochondrial
respiratory complexes, uncoupling cellular respiration. This in turn leads to oxidative stress and energy
deﬁcit that trigger critical downstream mechanisms, ultimately resulting in neuronal vulnerability and loss.
Here we review the molecular and cellular downstream effects triggered by mitochondrial dysfunction, and
the different experimental models that are obtained by the administration of selective mitochondrial toxins
or by the expression of mutant genes.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The basal ganglia (BG) are a richly interconnected group of brain
nuclei communicating with elements of the sensory, motor, cognitive,
and motivational apparatuses of the brain. In particular, BG play a key
role in the subtle regulation of voluntary and purposive movements
and are involved in motor learning and memory [188]. The
observation of humans suffering from neurodegenerative diseases
affecting the BG, such as Parkinson's disease (PD) and Huntington's
disease (HD), has provided the most widely accepted view of the
function of these structures, which has been further conﬁrmed
experimentally [2,55,74]. Notably, their pathophysiology includes
oxidative stress and impairment of mitochondrial energymetabolism,
in particular a speciﬁc dysfunction of complex I in PD and of complex
II in HD [26,159,160,170]. Mitochondria provide the bulk of energy
supply to the cell in the form of adenosine triphosphate (ATP).
Neurons are extremely sensitive to ATP depletion due to their highppement de Marseille-Luminy
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ll rights reserved.energy demand and for this reason they are strongly affected by
impairments of energy supply, which lead to necrotic or apoptotic
cellular death [76,129]. Interestingly, although mitochondrial dys-
function is involved in both PD and HD, the pattern of neuronal loss
observed in these two pathologies is different: the hallmark of PD is
the loss of substantia nigra pars compacta (SNc) dopaminergic neurons
[100,101], whereas HD is characterized by the selective degeneration
of striatal medium-sized spiny neurons using γ-aminobutyric acid
(GABA) as neurotransmitter and the relative sparing of cholinergic
interneurons [151]. Experimental and clinical data suggest that some
of the molecular mechanisms for such differential vulnerability
originate from the selective mitochondrial impairment underlying
PD and HD. Accordingly, chemical inhibition of either complex I or II
have led to useful and relevant experimental models of, respectively,
PD and HD. It should be mentioned, however, that although none of
these models fully reproduces the features of the human diseases,
they contributed to improve our knowledge on some of their
molecular, cellular and pathophysiological mechanisms. Such
mechanisms include, beside the disruption of mitochondrial energy
metabolism [8], common and speciﬁc molecular cascades that
ultimately lead to neuronal death. Here we will review these models
in the context of neurological diseases affecting the BG, with a
particular regard to the downstream mechanisms triggered by
mitochondrial dysfunction.
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As mentioned above, the BG are a network of interconnected
subcortical structures involved in the control of motor function and in
reward and cognitive processes [2,55,74]. The striatum (caudate and
putamen nuclei) is classically considered the main input nucleus of
the BG, receiving abundant glutamatergic afferences from the cortex
and in turn projecting to the output BG nuclei, i.e. the internal globus
pallidus (GPi) and substantia nigra pars reticulata (SNr). Such
projections are both direct and indirect via the external globus
pallidus (GPe) and the subthalamic nucleus (STN). Amore recent view
of BG organization (Fig. 1) now places both the striatum and STN as
the twomajor input stations, the latter belonging to the “hyperdirect”
cortex-STN-GPi/SNr pathway [107]. The balance between excitatory
(glutamatergic) and inhibitory (GABAergic) synaptic activity within
the BG is crucial for their physiological functioning and, accordingly,
disruptions of this balance are believed to underlie several hypo- or
hyper kinetic movement disorders, such as PD and HD [2,56,186,187].
It is thus of primary importance to further characterize their mole-
cular and cellular pathophysiological mechanisms, in order to develop
new therapeutic strategies able to slow disease progression and
neuronal loss.2.1. Parkinson's disease
PD is a debilitating neurodegenerative movement disorder with a
long course and a high prevalence (1.6 over 100 individuals aged
N65 years in the European Union) that increases with demographic
ageing [54]. The progressive loss of dopaminergic neurons of the SNc
characterizing PD leads to the disruption of the excitation/inhibition
balance in the BG and to the manifestation of the main PD symptoms:
postural instability, muscle rigidity, tremor and bradykinesia/akine-
sia. SNc neuron loss results in an excessive activity of glutamatergic
pathways of the BG, including the corticostriatal afferent pathway
[86,173] and STN efferent neurons [95], both playing a key role in the
expression of PD symptoms [35,79,161]. PD is also anatomopatholo-
gically characterized by cytoplasmic inclusions in dopaminergic
neurons called Lewy bodies, constituted by α-synuclein–ubiquitin
complexes [133]. Besides these evidences, the etiology of the disease
remains largely unknown and the available treatments, such asFig. 1. Schematic representation of the basal ganglia circuit. The structures and circuitry
of the BG are represented here, along with their connections to the cerebral cortex, the
thalamus and the brain stem/spinal cord. Note the three projection pathways to the
output BG structures (GPi/SNr): the “direct” one from the striatum, the “indirect” from
the striatum through GPe and STN, and the “hyperdirect” from the cortex through the
STN. The neurotransmitters utilized in the described projections are illustrated in
different colors. Abbreviations: GABA, γ-aminobutyric acid; GPe/i, globus pallidus pars
externa/interna; SNc/r, substantia nigra pars compacta/reticulata; STN, subthalamic
nucleus.administration of the dopamine precursor 3,4-dihydroxy-L-phenylal-
anine (L-DOPA) or deep-brain stimulation of BG structures, are only
symptomatic. Furthermore, motor ﬂuctuations and dyskinesia com-
plicate L-DOPA therapy in most patients within 5–10 years of
treatment initiation. The large majority of PD cases are idiopathic,
but a number of speciﬁc genetic mutations and exogenous factors
responsible for sporadic PD have been identiﬁed. Interestingly,
current evidence suggests that dysfunction of mitochondrial complex
I [52], as well as a possible aberrant interplay between dopamine and
α-synuclein [190], may play a major role in PD. In this context,
dysfunction of α-synuclein has been shown to indirectly but
signiﬁcantly impact on neuronal mitochondrial function, and there
is accumulating evidence for a close relationship betweenα-synuclein
and oxidative damage: overexpression of mutant α-synuclein
sensitizes neurons to oxidative stress and damage by dopamine and
complex I inhibitors, resulting in increased protein carbonylation and
lipid peroxidation in vitro and in vivo [1]. However, since the function
of α-synuclein is still unclear, further work is needed to understand
the molecular mechanisms involving this protein and dopamine
leading to the selective loss of SNc neurons characterizing PD.
2.2. Huntington's disease
HD is an autosomal dominant neurological disorder with a
prevalence of 4–8 people in 100,000 in Western Europe [94]. It is
characterized by the progressive loss of GABAergic medium-sized
spiny neurons of the striatum, while cholinergic interneurons are
spared [63]. HD symptoms include abnormal “dance-like”movements
(chorea), dystonia, cognitive deﬁcits and psychiatric disorders.
Treatments that can actually prevent the physical and mental decline
associated with HD are lacking, and available antichoreic drugs offer
patients only a limited respite from constant involuntary movements
and have long-term side effects [18,184]. Neuronal transplantation
provides some years of improvement and stability but not a
permanent cure for the disease [5]. The mutated gene responsible
for HD was identiﬁed in 1993 as the HD gene (IT15) by the HD
Collaborative Research Group [114]. Its protein product is huntingtin
(Htt) and, since its discovery, researchers are still elucidating the
function of both normal andmutant Htt (mHtt). Themutation causing
HD is an increased length of a CAG triplet repeat (N36) resulting in a
polyglutamine (polyQ) expanded mHtt. The expression of Htt, and
mHtt, is widespread in both the central and peripheral nervous
systems, and the mechanisms by which mHtt induces the selective
loss of striatal projection neurons are still poorly understood. In the
pathophysiology of HD, excitotoxic processes linked to N-methyl-D-
aspartate (NMDA) receptor activation [62], abnormal activity of
corticostriatal glutamatergic pathway [81,83], and mitochondrial
complex II dysfunction [24,84,112] have been hypothesized.
3. Biochemistry and physiology of the mitochondrion
Mitochondria generate most of the eukaryotic cell's supply of ATP
through the process known as oxidative phosphorylation, a biochem-
ical pathway ﬁrst characterized by Mitchell and Moyle in 1967 that
utilizes energy released by the catabolism of nutrients to synthesize
ATP [123]. Mitochondria participate in catabolic processes by several
biochemical pathways, including Krebs cycle (also known as the citric
acid or tricarboxylic acid cycle), and oxidation of fatty acids and amino
acids. The end result of these pathways is the production of two kinds
of energy-rich electron donors: reduced nicotinamide adenine
dinucleotide (NADH) and succinate. Electrons from NADH and
succinate are passed to oxygen that is reduced to water through
oxidative phosphorylation, a multi-step redox process occurring on
the mitochondrial inner membrane through the mitochondrial
electron transport chain. This chain is constituted by a set of ﬁve
large monomeric (I, II and V) or dimeric (III and IV) enzyme
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transferring proteins (Fig. 2). Complex I or NADH-coenzyme Q
oxidoreductase (also known as NADH dehydrogenase) is the ﬁrst
element in the electron transport chain [105]. The reaction catalyzed
by complex I consists in the reduction of coenzyme Q10 (or
ubiquinone) by NADH and the donation of two electrons. As the
electrons pass through complex I, four protons (H+) are pumped from
the matrix into the intermembrane space. Complex II or succinate-Q
oxidoreductase (also known as succinate dehydrogenase), which is
also a part of the Krebs cycle, oxidizes succinate to fumarate and
reduces coenzyme Q10 [36]. Complex III or Q-cytochrome c
oxidoreductase (also known as cytochrome c reductase or cyto-
chrome bc1 complex) catalyzes the oxidation of one molecule of
ubiquinol and the reduction of two molecules of cytochrome c
through a complex reaction called Q cycle, which pumps fourmore H+
in the intermembrane space [48]. Complex IV (also known as
cytochrome c oxidase) is the last element of the electron transport
chain and mediates the ﬁnal reaction, consisting in the transfer of the
electrons to O2 (that is reduced to 2 H2O accepting 4 electrons) while
pumping two H+ in the intermembrane space every two electrons
transported [33]. The ﬁnal step in the oxidative phosphorylation
pathway is ATP synthesis, catalyzed by complex V or ATP synthase
[21]. Interestingly, this mushroom-shaped giant protein complex is
found in all forms of life and functions in the same way in both
prokaryotes and eukaryotes [21]: it utilizes the energy stored in the
form of the H+ gradient (Δp) across the mitochondrial inner
membrane, generated by the electron transport chain, to synthesize
ATP from adenosine diphosphate (ADP) and phosphate (Pi).
Besides energy production through Krebs cycle and oxidative
phosphorylation, mitochondria have some other important roles for
the physiological functioning of the cell. For example, they participate
to Ca2+ homeostasis [90,127] in association with the endoplasmic
reticulum [147], contain circular DNA molecules (mitochondrial
genome) encoding for tRNAs, rRNAs, and complexes I, III, IV and V
[40], and participate to cellular metabolism and proliferation [115].
4. Mitochondrial downstream mechanisms in cell death
Mitochondria are essential to cell life. Accordingly, the loss of
mitochondrial ATP production leading to energy metabolism deﬁcit
can kill a cell by necrosis, and lack of ATP is particularly critical forFig. 2. Themitochondrial respiratory chain and the targets of mitochondrial toxins. Complexe
in green. The two electrons (2 e−) donated during the reduction of ubiquinone (Q) by NAD
which transfers them to O2 to generate water. During this process ten protons (H+) for each
generating a H+ gradient (Δp) across the inner membrane contributing to mitochondrial m
complex V, to synthesize ATP from ADP and Pi. The toxins utilized in experimental models of
also affects Krebs cycle, having a greater impact on cellular energy production.excitable cells such as neurons, in which the Na+/K+-ATPase uses
more than 40% of the available ATP to keep resting membrane
potential at physiological values [81]. However, mitochondria also
play an active role in cellular death by participating in complex
phenomena leading to apoptotic processes [77]. Indeed, these
organelles are involved in a number of key events in apoptosis
[75,77], the most critical of which is mitochondrial outer membrane
permeabilization (MOMP) occurring early during this programmed
death process [76]. MOMP consists in the release of proteins that
normally are found in the space between inner and outer mitochon-
drial membranes, such as cytochrome c and pro-apoptotic factors. The
mechanisms responsible for MOMP may involve the opening of the
mitochondrial permeability transition pore (mtPTP), leading to
collapse of Δp, loss of mitochondrial membrane potential (ΔΨm)
and matrix swelling [130], which can ultimately result in outer
membrane breaking [132]. The mtPTP putatively consists of the
voltage-dependent anion channel in the outer membrane, the
adenine nucleotide transporter translocator in the inner membrane,
cyclophilin D, and other molecules [174,175]. Other mechanisms do
not involve mtPTP and seem to be mediated by apoptosis-regulating
proteins of the Bcl-2 family (Bax and Bak) acting directly on the outer
membrane [76]. The consequences of MOMP are dramatic: as the
outer mitochondrial membrane breaks, a number of molecules are
released into the cytoplasm triggering downstream processes that
lead to apoptotic cell death (Fig. 3). These molecules include, in
particular: i) cytochrome c, which binds to the cytosolic protein Apaf-1
(apoptotic peptidase-activating factor 1) and to the nucleotide dATP,
and then recruits and activates pro-caspase-9 into caspase-9 [108]; ii)
several pro-caspases (2, 3, 8 and 9) [76] as well as apoptosis-inducing
factor (AIF) [167]; iii) caspase regulators such as Smac (second
mitochondria-derived activator of caspases), or its murine equivalent
DIABLO (direct IAP-binding protein with low pI), which removes IAPs
(inhibitor of apoptosis proteins) from caspase-IAP complexes, abro-
gating caspase inhibition [64].
Another important factor contributing to mitochondrial down-
stream processes leading to cell death is the release of reactive oxygen
species (ROS) and free radicals (Fig. 3). Mitochondria are the major
source of ROS, in particular superoxide anion (∙O2−) as a byproduct the
abovementioned Q cycle at complex III level [65,93]. Other ROS
include hydrogen peroxide (H2O2) produced from ∙O2− by superoxide
dismutase (SOD). Uncoupling electron transfer increases ROSs I to IV of themitochondrial respiratory chain catalyzing oxidative phosphorylation are
H are transported through complexes I, II, III and cytochrome c (Cyt c) to complex IV,
2 e− are pumped from the matrix to the intermembrane space by complexes I, II and IV,
embrane potential (ΔΨm). This gradient is utilized by ATP synthase (in red), also called
BG diseases target either complex I (for PD) or II (for HD). Note that complex II blockade
Fig. 3. Downstream mechanisms triggered by mitochondrial dysfunction converging
towards neuronal death. Mitochondrial damage and respiratory chain uncoupling by
mitochondrial toxins result in the decrease of ATP synthesis and in the increase in ROS
production, the former leading to energy failure promoting cell death, the latter further
contributing to cellular and mitochondrial damage. This can result in an impaired Ca2+
buffering that, together with excessive Ca2+ entering through NMDA receptors, leads to
increased Ca2+ levels both in the cytoplasm and in the mitochondria. Elevated
mitochondrial Ca2+ concentration triggers MOMP by opening of the mtPTP, resulting in
the collapse of Δp and ΔΨm, release of cytochrome c and other apoptosis-promoting
factors, and increased ROS production and Ca2+ accumulation. These downstream
effects, in turn, will further contribute to cellular and mitochondrial damage in a deadly
feedback cycle. Impaired ATP synthesis, excessive ROS production, Ca2+-mediated
excitotoxic processes, and release of pro-apoptotic factors all converge towards
neuronal death.
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to electron transfer uncoupling, which can result in a feedback
mechanism further increasing ROS production [77]. Besides being
harmful by directly damaging DNA, oxidizing fatty acids and amino
acids, and inactivating enzymes by oxidation, ROS can also trigger
several signaling pathways. Indeed, some of them exert a pro-survival
action, such as those mediated by ERK (extracellular regulated
protein), PI(3)K/Akt (phosphoinositide 3-kinase/Akt) and NF-κB
(nuclear factor κB), whereas some others can activate p53 tumor
suppressor protein transcription factor, JNK (c-Jun N-terminal kinase)
and p38 protein kinases that are linked to apoptosis, contributing to
the abovementioned pro-apoptotic events occurring during MOMP
[65]. Moreover, glutamate transporters [50] are also vulnerable to
ROS, resulting in reduced uptake function and build-up of extracel-
lular glutamate levels that can be toxic to neurons and astrocytes
[172]. Prolonged exposure to glutamate leads to hyperactivation of
ionotropic glutamate receptors [13,111] and to the concomitant inﬂux
of ions and water into the cell [43]. In particular, excessive activation
of NMDA receptors increases intracellular Ca2+ levels, which is known
to promote a great number of processes contributing to cell death
[60,81,88,121,128]. These processes include excitotoxicity, stimula-
tion of phospholipase A2 and Ca2+-dependent protein kinases, and
production of ROS and free radicals that may trigger a vicious cycle
worsening mitochondrial dysfunction that in turn predisposes
neurons to excitotoxic damage (Fig. 3).But how these mitochondrial downstream mechanisms leading to
cell death are triggered? Which of them are relevant to neurodegen-
erative diseases? A multitude of factors have been implicated in these
processes. The following sections will review the currently utilized
experimental models of mitochondrial impairment that attempt to
address the molecular, cellular and physiological mechanisms of BG
neurodegenerative diseases.
5. Mitochondrial complex I dysfunction and Parkinson's disease
Dysfunction of mitochondrial complex I has been associated to
sporadic forms of PD [52] and parkinsonism, the latter term referring
to a syndrome of tremor, rigidity, bradykinesia and postural instability
that, besides PD or “primary parkinsonism”, includes rare secondary
cases that may result from toxicity, head trauma or other medical
disorders [44,52]. Complex I derangement results in an enhanced
production of ROS that, in turn, further impairs mitochondrial
function in a vicious cycle [170], triggering the above described
downstream mechanisms leading to neuronal death. Accordingly,
neuroscientists took advantage of several selective complex I
inhibitors to develop experimental models relevant to PD [97].
5.1. 6-hydroxydopamine (6-OHDA)
The neurotoxin 6-OHDA is a structural analog of catecholamines
and has played a fundamental role in research on PD since the late
1960s [155,177], after the discovery of its lethal proprieties on
catecholaminergic neurons [148]. Neurotoxic effects of 6-OHDA occur
through a two-step mechanism involving accumulation of the toxin
into catecholaminergic neurons by the dopamine and noradrenaline
membrane transporters, followed by mitochondrial complex I
inhibition [17]. The action mechanism by which 6-OHDA reversibly
inhibits complex I still needs to be better characterized. However, it
seems that this toxin does not compete with NADH for its binding site
on the enzyme, but rather it binds to the enzyme–substrate complex
and the resulting enzyme–substrate–inhibitor complex has a reduced
catalytic activity [72]. 6-OHDA is toxic at both central and peripheral
level. However, since this molecule is unable to cross the blood–brain
barrier, it is toxic only when directly injected into the brain. The
selectivity of 6-OHDA for SNc dopaminergic neurons is thus achieved
by directly targeting this structure, in association or not with a
treatment blocking noradrenalin uptake such as desipramine. 6-
OHDA injection in the SNc or in the medial forebrain bundle produces
a massive (N90%) degeneration of dopaminergic neurons and speciﬁc
motor deﬁcits, some of which mimicking those of PD. 6-OHDA is
classically utilized in rats, but an increasingly number of papers now
reports this technique also in mice. However, 6-OHDA dopaminergic
denervation in rodents lacks key neuropathological and clinical
features of PD: Lewy bodies do not appear in neurons and tremor is
absent. Usually, 6-OHDA is injected unilaterally, and this is for two
main reasons: ﬁrst, the massive bilateral dopamine depletion
provoked by 6-OHDA is easily lethal in rodents, which moreover
need to be force-fed; second, animals with unilateral 6-OHDA lesion
have unilateral motor impairments that can be efﬁciently detected
and measured, such as ipsilateral akinesia and contralateral rotations
following administration of dopaminergic agents [37,86,178]. Some
scientists perform partial bilateral lesions (~60% of dopaminergic
loss) by injecting 6-OHDA in the dorsal striatum to target dopami-
nergic terminals, thus representing an “early stage” model of PD that
can also allow to study more complex behavioral changes such as
reaction time [3], a parameter also measured in humans [70]. The 6-
OHDA PD model has provided a considerable amount of information
at cellular and molecular level. For example, glutamatergic transmis-
sion in the BG is signiﬁcantly affected in rats with massive dopamine
denervation [162]: in vitro electrophysiological studies show an
enhanced glutamatergic activity of striatal medium-sized spiny
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two forms of synaptic plasticity described at corticostriatal synapse,
long-term depression (LTD) and long-term potentiation (LTP), are
lost in parkinsonian rats [28], as well as depotentiation of LTP
[28,142]. Another interesting feature of the 6-OHDA model of PD is
that it can be associated to antiparkinsonian therapies, such as L-
DOPA and chronic high-frequency stimulation of the STN [89], with
some interesting outcomes [29]. For example, L-DOPA treatment has
been shown to either ameliorate hypokinetic motor deﬁcits [113] or
to induce dyskinesia in hemiparkinsonian rats [143] depending on the
administration mode. Moreover, L-DOPA treatment is also capable to
reverse some cellular and molecular changes observed at striatal level
after unilateral 6-OHDA lesion in rats, in particular glutamatergic
hyperactivity at corticostriatal synapses [113], hypersensitization of
striatal D2-like dopamine receptors [4,144] and of group II metabo-
tropic glutamate receptors [146], as well as endocannabinoid system
abnormalities [87,113]. Similarly, STN stimulation is also effective in
progressively reducing akinesia and reversing glutamatergic hyper-
activity at corticostriatal synapses [86].5.2. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
This neurotoxin was discovered when drug-addicted Californians
accidentally injected with “synthetic heroin” (1-methyl-4-phenyl-4-
propionoxypiperidine, MPPP or desmethylprodine) contaminated
with MPTP and suddenly developed parkinsonian symptoms
[7,102]. MPTP is a highly lipophilic mitochondrial complex I inhibitor
that easily crosses the blood–brain barrier and can thus be
administrated systemically to obtain experimental PD models [149].
It becomes toxic through its transformation to 1-methyl-4-phenyl-
2,3-dihydropyridinium (MPDP+) by the enzyme monoamine oxidase
B (MAO-B) expressed by glia and serotoninergic neurons [99], and its
subsequent spontaneous oxidation to 1-methyl-4-phenylpyridinium
(MPP+) [165,171]. The dopamine transporter (DAT) then carries
MPP+ into dopaminergic neurons, where it is accumulated into
synaptic vesicles by the vesicular monoamine transporter (VMAT).
Once in the cell, it can enter mitochondria using ΔΨm driving force
where it blocks complex I [131,152,164,166]. Various protocols of
MPTP administration inmice (acute vs. chronic; repeated injections of
lowdoses vs. a single high dose, etc.) exist in the literature [120], while
the rat appears to be refractory to this toxin. Chronic intoxicationwith
low doses of MPTP is also used in monkeys, in which it mimics at best
the motor symptoms of PD including tremor, bradykinesia, muscle
rigidity and postural instability, as well as some neuropathological
features including the massive loss of SNc neurons. [97,124,166]. On
the other hand, degeneration of nigrostriatal dopamine neurons is not
accompanied by themore general loss of monoaminergic cells and the
presence of Lewybodies observed in PD, at least in non-chronicmodels
[67]. The MPTP model has been particularly useful for studying the
functional changes occurring in the primate BG after dopamine
depletion, providing insights into the pathophysiology of PD. For
example, STN neurons recorded from awake monkeys showed an
increased rate of spontaneous ﬁring activity with periodic oscilla-
tions at low β-frequency, which in humans is highly correlated with
tremor [12,15,117], conﬁrming that this structure becomes hyperac-
tive in PD and contributes to the disruption of BG functioning.
Moreover, the rationale for targeting STN by deep-brain stimulation
arose from the primateMPTPmodel [89]. Recently, some studies using
chronicMPTP intoxication inmice showed inhibition of the ubiquitin–
proteasome systemparalleled by the apparition of neuronal inclusions
containing ubiquitin and α-synuclein [66,119]. Interestingly, such
alterations were reduced in mice lacking α-synuclein [66], further
supporting the involvement of this protein in the pathophysio-
logical processes of PD [190]. In MPTP-treated mice some interesting
motor impairments relevant to PD can be detected by a number ofbehavioral tests that are sensitive to subtle changes in dopamine levels
[118].
Concerning the mechanisms of MPTP toxicity, NMDA receptor and
inducible nitric oxyde synthase (iNOS) have also been implicated in
MPTP-mediated loss of SNc neurons, because such neurodegeneration
was reduced by NMDA receptor antagonists [176], in mice lacking
iNOS [109] or by an anti-inﬂammatory compound (of the diindolyl-
methane class) suppressing NF-κB-dependent expression of iNOS
[34]. Other reports have suggested a neurodegenerative mechanism
based on mitochondrial downstream apoptotic processes [17], which
involve up-regulation of JNK [157] and Bax [180], release of
cytochrome c and activation of caspase-3 and -9 [183]. Accordingly,
systemic pharmacological blockade of JNK or p53 (which regulates
Bax) resulted in reduced damage to nigrostriatal neurons after MPTP
intoxication [59,157].
5.3. Rotenone
Rotenone is a complex I inhibitor used in broad spectrum
insecticides, piscicides and pesticides. It can naturally be found in
the roots and stems of several tropical plants such as the jícama vine
plant (Pachyrhizus erosus). Rotenone is highly lipophilic and, unlike
MMP+, it does not need to be actively transported. Thus, it can quickly
and easily accumulate in tissues and then reach the brain [78].
Systemic (intravenous) administration of rotenone in rats induces a
highly selective degeneration of SNc neurons paralleled with hypoki-
nesia and rigidity, and cytoplasmatic inclusions containing ubiquitin
and α-synuclein [14,27]. The administration route of this inhibitor
seems essential for the set up of experimental PDmodels, since chronic
intranasal inoculation failed to induce dopamine neuron degeneration
[154]. The action mechanisms of rotenone are still poorly character-
ized, but evidence from experimental in vitro and in vivo PDmodels by
chronic intoxication suggest that this toxin causes a delayed depletion
of glutathione, which is accompanied by oxidative damage to proteins
and DNA [78]. Electrophysiological data show that rotenone acute
application on corticostriatal slices produces an early hyperpolariza-
tion of striatal cholinergic interneurons, followed by a late depolariz-
ing response that seems linked, respectively, to activation of ATP-
sensitive K+ channels and decreased Na+/K+-ATPase function [19].
More recent electrophysiological studies targeted striatal spiny
neurons, which respond by a marked membrane depolarization
resulting in the loss of ﬁeld potential, coupled to an increased release
of excitatory amino acids and dopamine. Interestingly, these effects
were not attenuated by acting on glutamatergic synaptic transmission
[39,47] but theywere reduced by antagonists of dopamineD2-like [47]
or adenosine A2A receptors [11], suggesting that monoaminergic and
purinergic systemsmayplay a role in the selective toxicity of rotenone.
5.4. Paraquat
Paraquat is the trade name for 1,1′-dimethyl-4,4′-bipyridinium
dichloride, a structural analog ofMPP+ and one of themost widely used
pesticides and herbicides in the world. It is lipophilic and enters easily
into the cell where is taken up across the mitochondrial inner
membrane by a carrier-mediated and ΔΨm-dependent process, and
once in the matrix it is reduced by complex I. The reduced form of
paraquat then reacts with oxygen to form ROS (in particular ∙O2−) and
cause mitochondrial oxidative stress leading to neuronal death [45].
Accordingly, synthetic SOD/catalase mimetics can protect dopaminer-
gic neurons both in cell lines and in mice treated with this toxin [140].
An epidemiological association has been found between the use of
paraquat in agriculture and the incidence of parkinsonism [57], and this
toxin is now used to model PD. Some mechanisms underlying acute
paraquat neurotoxicity begin now to be elucidated. At molecular level,
they seem to involve sequential phosphorylation of JNK and c-Jun, and
the activation of caspase-3, leading to apoptosis [139]. At the cellular
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suggesting that a decreased excitability and function of these cells in the
SNcmaycontribute to thepathogenesis of PD [104]. Long-termparaquat
administration (up to 24 weeks) has been shown to produce a slowly
progressing degeneration of dopaminergic neurons of the SNc [135] and
the ventral tegmental area (a source of the mesocortical dopaminergic
projection) [134], leading to delayed deﬁcits in dopaminergic trans-
mission that resemble early presymptomatic stages of PD. However,
another study with chronic exposure to paraquat (intranasal inocula-
tion) in mice did not report dopaminergic loss, but this toxin induced
severe hypokinesia and vestibular damage [154],
5.5. Manganese
Although manganese intoxication is not properly an experimental
model of PD, its action mechanisms are relevant to this disease
because they involve mitochondrial complex I inhibition. Manganese
(Mn) is an essential trace element and is required for several
physiological enzymatic reactions. Exposure to excessive levels of
this metal through inhalation of manganese-containing dust can
evoke a syndrome with psychiatric disturbances and severe extrapy-
ramidal motor dysfunctions closely resembling those of PD, called
manganism. Clinical manifestations of manganism arise from focal
injury to the BG due to the fact that these nuclei accumulate most of
the excess manganese compared with other brain regions. The
mechanisms of the cellular damage caused by this element have
been attributed to its capacity to produce toxic levels of free radicals
and induce mitochondrial dysfunction, thus enhancing ROS produc-
tion [58,91]. Manganese is sequestered by brain and liver mitochon-
dria via the mitochondrial Ca2+ uniporter [71], and its toxicity seems
to result from a direct and/or indirect inhibitory effect of Mn(III) and
Mn(II) on complex I leading to oxidative stress [42,68]. Moreover, Mn
(II) catalyzes the auto oxidation of dopamine to dihydrobenzothiazine
(DHBT) and then to 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-
1,4-benzothiazine-3-carboxylic acid (DHBT-1), which is a complex I
inhibitor [163]. We have shown that chronic manganese intoxication
in rats (MnCl2 dissolved in drinking water) induces a hyperactivation
of corticostriatal glutamatergic afferences [38], reminding that
observed after 6-OHDA lesion, paralleled by an enhanced sensitivity
of presynaptic D2-like dopamine receptors [32].
6. Gene mutation, mitochondria and Parkinson's disease
Around 5% of PD cases are familial forms that have an earlier onset
(~45 years) [53] and that arise from the mutation of several identiﬁed
genes, in particular parkin and PINK1 [phosphatase and tensin
homologue (PTEN)-induced putative kinase 1] [1,192]. Parkin and
PINK1 are involved in autosomal recessive PD (ARPD), and they are
particularly interesting here because both clinical and experimental
evidence have associated their mutation with mitochondrial
dysfunction.
6.1. Parkin
Parkin is a 465 amino acid E2-dependent E3 ubiquitin ligase
involved in protein ubiquitination and removal of damaged proteins.
A large variety of homozygous and heterozygous mutations of parkin
gene have been reported, all of them abolishing or reducing parkin
activity and representing ~50% of ARPD cases [1]. Severe mitochon-
drial pathology and increased vulnerability to oxidative stress have
been shown in Drosophila null mutants [80]. In mice, deletion of
parkin exon 3 resulted in reduced excitability of striatal medium-sized
spiny neurons and behavioral deﬁcits sensitive to nigrostriatal
pathway dysfunction [73]. Moreover, these animas had an impaired
mitochondrial function paralleled by a decreased expression of
complex I and IV subunits [136]. On the other hand, deletion of eitherexon 2 or 3 did not cause dopaminergic neuron degeneration [73,96],
thus questioning the validity of parkin mutant mice as a PD model
[141].
The mechanisms by which parkin is linked to mitochondrial
function are not yet completely elucidated. In ceramide-mediated
apoptosis, parkin seems to promote the degradation of protein
substrates localized in or around mitochondria, delaying MOMP and
subsequent cytochrome c release and caspase-3 activation [51]. Other
indirect actions of parkin onmitochondria have been hypothesized, all
linked to its role in protein ubiquitination and degradation [1].
Recently, it has been shown that a wide array of complex I inhibitors,
including 6-OHDA,MPP+, paraquat, NO and iron, as well as dopamine,
all altered parkin solubility, leading to parkin aggregation and thus
compromising its neuroprotective function [185]. Overall, parkin
seems to play an important role in cell protection against oxidative
stress, and its mutation disrupts this function as well as its role as
ubiquitin ligase, leading to an impaired removal of mitochondrion-
associated damaged proteins and thus tomitochondrial damage [192].
Interestingly, dopamine covalently modiﬁes parkin, which results in
the loss of its activity [103] and suggests a possible mechanism for the
selective loss of dopaminergic neurons in ARPD as well as in idiopatic
PD. Furthermore, it has been shown that overexpression of Pael-R
(parkin associated-endothelin-receptor-like receptor, an endoplasmic
reticulum-associated substrate of parkin) leads to Pael-R aggregation,
which in turn results in endoplasmic reticulum stress and dopami-
nergic neuron death. This effect was alleviated by parkin over-
expression as well as dopamine synthesis inhibition, implicating
dopamine in such toxic aggregation process [192].
6.2. PINK1
Mutations in PINK1 have been identiﬁed in three large consan-
guineous families, two Italian and one Spanish, in which several cases
of ARPD were reported [179]. PINK1 is a 581 amino acid protein
expressed ubiquitously, whose transcription is activated by PTEN and
whose N-terminal kinase domain targets mitochondria. PINK1 muta-
tions have been reported to be distributedmostly in the region coding
for this domain. In particular, the G→A amino acid substitution in
exon 4 (G309D) found in the Spanish family, when overexpressed in a
neuroblastoma cell line, impaired PINK1 kinase activity, its interaction
with mitochondria and its import inside these organelles, resulting in
the reduction of ΔΨm. Conversely, overexpression of wild-type PINK1
decreased the release of cytochrome c from mitochondria both in
control conditions and in staurosporine-induced stress [179]. How-
ever, the direct link between PINK1 andmitochondria still needs to be
elucidated. Interestingly, data arising from Drosophila suggest that
PINK1 and parkin may act in a common pathway in the pathogenesis
of PD, because PINK1 loss of function mutation could be rescued by
using transgenic expression of parkin [168,191]. Moreover, recent
evidence in Drosophila and mammalian cell culture showed that
parkin phosphorylation by PINK1 promotes its mitochondrial trans-
location, further suggesting a possible pathological mechanism for PD
associating these two proteins [98].
7. Mitochondrial complex II dysfunction and Huntington's disease
Complex II or succinate dehydrogenase (succinate-Q oxidoreduc-
tase) participates not only to oxidative phosphorylation, but also to
the Krebs cycle. Its experimental or accidental blockade thus results in
a dramatic ATP depletion and, interestingly, in a neurodegenerative
pattern and motor symptoms closely resembling those of HD. Several
toxins have been discovered being able to selectively block this
enzyme, and scientists took advantage of this for developing models
relevant to HD. In particular, 3-nitropropionic acid (3-NP), which was
identiﬁed in the 1950s in a toxic tropical ﬂowering plant belonging to
the Fabaceae family, but is also present in other plants and fungi. It has
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nitroacrylate, which then irreversibly inhibits the enzyme [46].
Accidental exposure to 3-NP mimics the pathophysiology of HD in
humans and, accordingly, chronic systemic 3-NP administration has
long been used as an experimental HD model both in rodents and
monkeys [22–25,112,137,189]. 3-NP produces brain lesions that are
mostly conﬁned to the striatum, with selective loss of medium-sized
spiny neurons and relative sparing of interneurons [10,137]. Other
complex II blockers also used in research include malonic acid (MA)
[82] and the more cell-permeable methylmalonic acid (MMA) [116],
two synthetic dicarboxylic acids. They compete with succinate but do
not react with the enzyme, thus their inhibitory effect is reversible,
and chronic MA treatment produces lesions similar to those observed
with 3-NP [9,82].
At functional level, rats with systemic subacute 3-NP administra-
tion develop motor symptoms resembling striatal-induced dystonia
[10,92], impaired responses in the cross-maze task and perseverative
behavior [145]. Motor troubles relevant to HD have been observed in
tufted capuchin monkeys (Cebus apella), which showed spontaneous
and apomorphine-induced dystonia and dyskinesia after two months
of chronic 3-NP treatment [153]. Spontaneous and apomorphine-
induced dystonias of foot and leg, and some dyskinesias of the
hindlimb were also reported in baboons, which also showed
signiﬁcant impairments in a test designed to assess the functional
integrity of the frontostriatal pathway in both humans and nonhuman
primates [137].
Themechanisms of action underlying the selective toxicity of 3-NP,
MA and MMA have been in part elucidated. The strong impairment in
energy metabolism due to succinate dehydrogenase inhibition
depletes ATP levels, leading to Na+/K+-ATPase dysfunction and sub-
sequent neuronal membrane depolarization, followed by de-inactiva-
tion of NMDA receptors by relieving voltage-dependent Mg2+ block
[81,83]. In line with these ﬁndings, it has been shown that acute
application of 3-NP or MMA on brain slices induces a potentiation of
NMDA receptor-mediated synaptic excitation, resulting in a LTP of
corticostriatal synaptic transmission [30], as well as other alterations
of striatal synaptic plasticity [145]. Interestingly, NMDA receptor-
mediated potentiation is observed in medium-sized spiny neurons
but not in cholinergic interneurons [30], is promoted by NR2B con-
taining NMDA receptors [39], is induced by the activation of the
metabotropic glutamate subtype 1 (mGlu1) receptor/protein kinase
C pathway as well as dopamine D2-like receptors, and is negatively
regulated by D1-like receptors [85]. Accordingly, acute 3-NP treat-
ment modulates the expression of several genes involved in
glutamatergic and dopaminergic signaling [125]. These evidences
suggest that NMDA receptor-dependent mechanisms may underlie
the vulnerability of striatal medium-sized spiny neurons to complex
II dysfunction, and that the selective loss might be attributed to the
high contents of dopamine in the striatum. Another striking difference
in the reactivity to complex II blockade between striatalmedium-sized
spiny neurons and cholinergic interneurons is that the former respond
to the toxin by a depolarization,while the latter by a hyperpolarization
that might represent a neuroprotective mechanism [158]. The
excitotoxic dopamine-mediated hyperactivation of NMDA receptors
conﬁned to striatal spiny neurons, combinedwith energy failure, could
converge into a common downstream mechanism leading to the
selective neuronal loss observed during HD. Such neurodegeneration
seems also to involve acute inﬂammatory processes, as suggested by
the activation of NF-κB by in vitro 3-NP application [126]. Moreover, an
apoptotic mechanism might also participate, as suggested by the
progressive activation of p53 and JNK, followed by c-Jun activation and
expression, induced in the striatum of 3-NP intoxicated rats and in
cultured neurons treated with this toxin [69]. Moreover, enhanced
expression of the apoptosis markers Bcl-2 and caspase-3 has also been
detected in the caudate nucleus of HD patients [181], as well as in the
striatum of rats intoxicated with 3-NP [182].The 3-NP model of HD has also been successfully used to test
neuroprotective strategies that might be helpful in slowing the
progression of the disease. For example, it has been shown that the
uncompetitive NMDA receptor antagonist memantine, which is
currently used for Alzheimer's disease treatment, can reduce the
irreversible loss of corticostriatal ﬁeld potential caused by acute 3-NP
application [169]. Another study showed that striatal in situ
continuous delivery of CNTF (ciliary neurotrophic factor), an
endogenous astrocyte activator, could reduce striatal neurodegenera-
tion, cognitive impairment and motor symptoms in primates
chronically treated with 3-NP [16]. Interestingly, CNTF-mediated
neuroprotection seems to occur by improving glutamate handling
[61], in particular by enhancing the function of glutamate transporters
(unpublished observation), further suggesting a role of glutamate-
mediated toxicity in the progressive loss of striatal medium-sized
spiny neurons in HD.
8. Mutant huntingtin, mitochondria and Huntington's disease
There is increasing evidence suggesting that mitochondrial
dysfunction characterizing HD is associated to the expression of
mHtt [20]. For example, it has been shown that mitochondrial
impairment occurs even in asymptomatic carriers expressing mHtt
with 41–47 CAG repeats [156], and mitochondria isolated from early
HD patients and YAC72 transgenic mice have reduced Ca2+ buffering
capacity [138]. Furthermore, culture cells expressing mHtt showed
impairment of mitochondrial respiration and ATP synthesis [122]. But
which is the molecular link between mHtt and mitochondria leading
to the dysfunction of these organelles? One candidate is p53: mHtt
has been shown to bind to p53, up-regulating its transcriptional
activity and increasing its levels in PC12 cells, primary neuronal
cultures, mHtt-Tg mice and post-mortem brains of HD patients [6].
This, in turn, increases the expression of PUMA (p53 up-regulated
modulator of apoptosis) and BAX (Bcl-2-associated X protein), two
pro-apoptotic members of the Bcl-2 family, leading to mitochondrial
damage and cell death [6]. Another possible molecular link between
mHtt and mitochondrial dysfunction is PGC-1α [peroxisome prolif-
erator-activated receptor (PPAR)-γ coactivator 1α). PGC-1α is a key
element that co-regulates the transcription of some cellular programs
modulating mitochondrial respiration, oxidative stress defense and
adaptive thermogenesis. In particular, PGC-1α binds to nuclear
transcription factors regulating nuclear-encoded mitochondrial
genes such as cytochrome c, mitochondrial transcription factor A
and complex I–V components [150]. At molecular level, mHtt
interferes with the PGC-1α promoter leading to reduced PGC-1α
transcription [49]. Interestingly, PGC-1α knock-out mice showed
microvacuolation of neuropil and neurons in the striatum, as well as
an abnormal energy metabolic phenotype [106,110]. Furthermore,
PGC-1α is a potent suppressor of ROS production, suggesting that
reduced expression or loss of this transcriptional co-regulator might
sensitize neurons to oxidative stress [20]. Accordingly, PGC-1α is
decreased in striatal medium-sized spiny neurons, but not in
interneurons, of R6/2 HD mice, suggesting a possible mechanism for
the selective neuronal loss characterizing HD [49]. Finally, besides
these indirect molecular links, mHtt binds directly to the mitochon-
drial outer membrane, forming large clusters that can impair
mitochondrial function, change their morphology and interfere with
their intracellular movement [20,41].
9. Conclusions
The experimental use of selective mitochondrial toxins allowed
the development of animal models of neurodegenerative diseases
involving the BG. Uncoupling complex I or II leads to physiological,
behavioral and anatomopathological alterations in rodents and
primates that mimic those observed, respectively, in PD and HD.
158 P. Gubellini et al. / Biochimica et Biophysica Acta 1802 (2010) 151–161The major contribution of these experimental models, however, is
that they provided precious insights to understand the mechanisms
underlying PD and HD onset and progression. In particular, elucida-
tion of the events occurring at the cellular level leading to neuronal
death offered us several clues on possible new treatments for PD and
HD targeting speciﬁc molecules that participate to the pathogenic
cascade triggered by mitochondrial dysfunction.
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